Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?

被引：20

作者：

Cho, Leslie ^{[1
]}

Kaunitz, Andrew M. ^{[2
]}

Faubion, Stephanie S. ^{[3
]}

Hayes, Sharonne N. ^{[4
]}

Lau, Emily S. ^{[5
]}

Pristera, Nicole ^{[6
]}

Scott, Nandita ^{[5
]}

Shifren, Jan L. ^{[5
]}

Shufelt, Chrisandra L. ^{[4
]}

Stuenkel, Cynthia A. ^{[7
]}

Lindley, Kathryn J. ^{[8
]}

机构：

[1] Cleveland Clin, Akron, OH USA

[2] Univ Florida, Coll Med Jacksonville, Jacksonville, FL USA

[3] Mayo Clin, Jacksonville, FL USA

[4] Mayo Clin, Rochester, MN USA

[5] Massachusetts Gen Hosp, Boston, MA USA

[6] Univ Washington, Med Ctr, Seattle, WA USA

[7] Univ Calif La Jolla, San Diego Sch Med, La Jolla, CA USA

[8] Vanderbilt Univ, Med Ctr, Nashville, TN USA

来源：

CIRCULATION | 2023年 / 147卷 / 07期

关键词：

cardiovascular diseases; coronary artery disease; hormone replacement therapy; hyperlipidemias; hypertension; menopause; venous thromboembolism; ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; POSTMENOPAUSAL WOMEN; CARDIOVASCULAR-DISEASE; UNITED-STATES; VENOUS THROMBOEMBOLISM; REPLACEMENT THERAPY; POSITION STATEMENT; METABOLIC SYNDROME; EQUINE ESTROGEN;

D O I：

10.1161/CIRCULATIONAHA.122.061559

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women's health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.

引用

页码：597 / 610

页数：14

共 50 条

[1] Menopausal hormone therapy: who, why, what and for how long?
Altman, A.
[J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2015, 122 : 366 - 367
[2] HORMONE REPLACEMENT THERAPY - STARTING WHEN, WITH WHAT AND HOW LONG
BRECKWOLDT, M
KECK, C
[J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 1994, 54 (05) : M67 - M69
[3] Stopping systemic menopausal hormone therapy: Why, when and how
Faubion, Stephanie S.
Kaunitz, Andrew M.
[J]. MATURITAS, 2016, 89 : 3 - 4
[4] Renal Replacement Therapy in the Age at whom, when, how, how long?
Hoffmann, U.
Sieber, C.
[J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 (31-32) : 1568 - 1571
[5] What works for whom, when and how?
Seers, Kate
[J]. PAIN, 2009, 143 (03) : 167 - 168
[6] Discontinuation of menopausal hormone therapy: what are the symptoms and how should they be managed?
Sabrina Gill
[J]. Nature Clinical Practice Endocrinology & Metabolism, 2006, 2 (4): : 192 - 193
[7] Preoperative therapy: what, when and for whom?
von Minckwitz, G.
[J]. ANNALS OF ONCOLOGY, 2008, 19 : 113 - 116
[8] When, for How Long and in Whom Should Medical Expulsive Therapy be Used?
Monga, Manoj
[J]. JOURNAL OF UROLOGY, 2014, 191 (03): : 581 - 581
[9] Vasopressin Antagonists for the Treatment of Acute Decompensated Heart Failure: When, for Whom, for How Long, and on What Standard Therapy?
Filippatos, Gerasimos
Parissis, John T.
[J]. JOURNAL OF CARDIAC FAILURE, 2008, 14 (08) : 648 - 650
[10] Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?
Thomas, C.
Ohlmann, C-H
[J]. UROLOGE, 2020, 59 (06): : 665 - 672

← 1 2 3 4 5 →